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Gender Equity in Clinical Trials in Canada: Aspiration or Achievement?
Patricia Peppin and Roxanne Mykitiuk
(Fall 2008) 1:2 International Journal of Feminist Approaches to Bioethics 100124.

Achieving gender equity in clinical trials requires that women be included in sufficient
numbers to carry out analysis, that those sub-sample analyses be carried out, and that
results be communicated in such a way as to expand medical knowledge, inform policy
decisions and educate patients. In this article, we examine the extent to which Canada
promotes gender equity through its laws and guidelines, viewed within the context of its
drug safety system and its research ethics board structure. We analyze the structuring of
information by the pharmaceutical industry and consider the impact of its promotional
activities on the state of gender knowledge and health. In the final section we propose
ways to improve the structuring of health information to promote gender equity.

I

Introduction

The case for inclusion of women in clinical trials has been well made since the 1980s.1 A number
of considerations inform the need for sex and gender inclusion in the clinical trial process. Most
importantly, unless drugs are tested on the entire population that will use them once the drug is
on the market, we cannot be satisfied that health and safety have been adequately protected. A
study of trials and meta-analyses of drug therapies for myocardial infarction published in five
leading medical journals between 1992 and 1996 reveal that women were poorly represented
(mean: 24%), and that just under a third (32%) of 42 reports reviewed provided results based on
gender, while even fewer (12%) discussed the differences between men and women.2
Cardiovascular disease is the leading cause of death of women in Canada and globally.
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Analysis of the data for individual sub-groups is essential to increasing our knowledge of a
drug’s effects. A study of clinical trials of Vioxx found that more women than men had been
included (74 per cent were women) but that 80 per cent of the trials included no description of
the drug’s efficacy by sex. Only one trial reported adverse effects data by sex.3 This study also
notes that in the Spanish trials of Vioxx, 78 per cent of the reported side effects of Vioxx were
found in women.4 Further support for gender inclusion is found in the clear evidence of sexbased differences in pharmacokinetics and pharmacological effect (pharmacodynamics).5 These
results have implications for dosage as well as the impact of the drug. For example, one postmarket study on paroxetine (Paxil/Seroxat) notes “the complete lack of coherent science-based
advice on dosage…[which] is essential for the safe and effective use of most drugs, but is
available for few.”6

The need for women’s health research has been amply demonstrated through the Women’s
Health Initiative [WHI], the first longitudinal study of women’s health. Starting in 1991, the
WHI carried out a fifteen year program of research through clinical trials and an observational
study on leading causes of death and disability among postmenopausal women: cardiovascular
disease, cancer, and osteoporosis.7 Their clinical trial of hormone replacement therapy
challenged conclusions about its benefits and risks, and led significant numbers of women to
stop the therapy.8 Similarly, their study on long-term aspirin use revealed a differential impact
on heart health as between men and women.9

By the 1990s women’s activists had become concerned about the lack of representation of
women in clinical trials and research. Women’s health became the subject of international
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agreement at the United Nations Fourth World Conference on Women in Beijing in 1995. 10 The
Declaration produced at the Conference guarantees, among other things, equal access and
treatment to men and women in education and health care. Canada adopted the Beijing
Declaration and established The Federal Plan for Gender Equality in the same year. The
Federal Plan called for research into participation in clinical trials and research. Health Canada
also created a guideline on inclusion in clinical trials in 1997.11 Meanwhile, the federally funded
research councils added a non-exclusion clause on the basis of sex to the Tri-Council Policy
Statement, Ethical Conduct for Research Involving Humans [TCPS].12 In the first part of this
article, we will assess the merits of these and other developments in gender inclusion in drug
safety research, and of the Research Ethics Board [REB] system through which they are
implemented. In the second part we will analyze the role of the pharmaceutical industry in
structuring health information and the way these activities undermine gender equity. This
analysis is undertaken to assess whether gender equity in clinical trials has been achieved, or is
still an aspiration.

II

Canadian position on inclusion

Context
Proper inclusion in clinical trials requires representation in sufficient numbers to permit analysis
of data of sub-populations such as women and men, and elderly women and men, and members
of ethnic minorities. To achieve the benefits of representation, it is necessary for researchers to
perform the sub-sample analyses for each group in relation to the others. As well, to achieve
gender equity, researchers need to consider the data in light of social factors that inform the
concept of gender. These environmental and behavioural factors13 comprise the social
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determinants of health, and include income and social status, physical environments, culture, and
sex.14 The unique health status of poor aboriginal women living in remote locations provides
stark evidence of the relevance and significance of these determinants.15 Social determinants of
health affect the ways women and men use the health care system, view their health, use
prescription medications, and participate in clinical trials.16 To further respect women’s
interests, women need to be empowered to make their own decisions about participation in trials.
Also, some trials should take place during pregnancy. Finally, women should not be pressured to
participate by the drug industry or physicians, or be made to undergo trials as a means of
obtaining otherwise inaccessible care.

Canada has taken a variety of steps to establish standards and organizations to implement its
international commitments in the area of women’s health. This institutional framework provides
the context for a discussion of gender inclusion in research and clinical trials in particular and
gender equity in health more broadly. Canada ratified the Convention on the Elimination of All
Forms of Discrimination Against Women, article 12 of which requires the elimination of
discrimination in the field of health and health care, with specific reference to pregnancy
services. In 1993, the Canadian government established the Bureau of Women’s Health within
Health Canada (now referred to as the Bureau of Women’s Health and Gender Analysis). The
Bureau’s mission is to promote equitable health outcomes for women and men, boys and girls.
In 1999 the Bureau published the Women’s Health Strategy, which focuses specifically on
gender-based analysis, access and accountability.17 In 2000 Canada reiterated its 1995
commitment to the Beijing Declaration at the United Nations and published Health Canada’s
Gender-based Analysis Policy [GBA Policy], which provides an analytic framework within
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which to assess how government policies, programs, and legislation contribute to gender equality
and to more equitable health outcomes.18 The Bureau of Women’s Health and Gender Analysis
describes GBA as using sex and gender to perceive social differences and contexts and to
identify how these conditions affect health status and interactions with the health care system. 19

As an example, they discuss the clinical trials policy, stating that applying GBA reveals gender
bias and raises questions about the scientific validity of studies, resulting in the policy now
requiring inclusion of both sexes unless the drug is intended for use in only one sex. The GBA
Policy recognizes that a gender perspective is essential to health policy and notes that full
integration of gender analysis into planning and operations is required.20 The Women’s Health
Strategy provides the framework for integrating gender-based analysis into programs and
policies. The Strategy outlines 64 key activities to meet its goals. One activity consists of
monitoring the implementation of the inclusion guideline for women in clinical trials.

The Women’s Health Bureau supports the Canadian Women’s Health Network [CWHN] and
five Centres of Excellence for Women’s Health across the country. The CWHN has suggested
that a review of the Women’s Health Strategy would be timely, noting that in 2005 Health
Canada told the Standing Committee on the Status of Women that it planned to review the
Strategy.21 Olena Hankivsky, in her review for the CWHN of Canada’s progress on women’s
health since the Beijing Declaration, concludes that progress has been made in the previous ten
years, but that “much more work needs to be done to realize the federal government’s
commitments to Beijing and Beijing+5, among other international obligations”.22 Hankivsky
points to six specific problems, among them the lack of a formal mechanism to ensure genderbased analysis in health research, the under-representation of women in health and science
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careers, gender bias in research methods and priorities, and the government’s failure to regulate
health matters in areas where it has the authority to do so, as it does with drug advertising. In
addition, she notes that while the Women’s Health Strategy had taken note of the need to be
sensitive to diversity, it needs to take full account of the inequities experienced by women who
are poor, disabled, aboriginal, or elderly.23

Drug approval process
The legislation governing drug approval is the Food and Drugs Act, a federal statute.24 The Act
and the Food and Drug Regulations are silent on gender equity.25 In 1997, Health Canada issued
a guideline on inclusion to apply to all clinical trials, Inclusion of Women in Clinical Trials.26
The guideline asserts that, “[d]rugs should be studied prior to approval in subjects representing
the full range of patients likely to receive the drug once it is marketed”. The guideline also states
that, “patients of both sexes should be included in the same trials in numbers adequate to allow
detection of clinically significant sex-related differences in drug response” and further, that
“[a]nalyses to detect the influence of sex should be carried out both for individual studies and in
the overall integrated analysis of efficacy and safety.”
The guideline’s stated intent is to “encourage the inclusion of women, especially women of
child-bearing potential, at the earliest stages of drug development” so that sex-related differences
may be identified early and taken into account in Phase III safety and efficacy trials, and to
ensure that data will be available to inform physicians and patients about sex-related drug
qualities. This point is significant since it is at the early stage of research that the
pharmacokinetics and pharmacological effects are identified. As the guideline notes, these
differences might occur in dosage responses, maximum size of effect, or adverse effect risk. The
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guideline states that exclusion from early trials out of concern for fetal toxicity is not necessary
because women can take adequate precautions against becoming pregnant and exposing a fetus
to potential danger.27 According to the guideline, the decision of whether to enroll pregnant or
lactating women in a particular trial needs to be individualized. Risk should be assessed by
patients, their doctors, the manufacturer, and REBs, with oversight by the Therapeutic Products
Directorate.
The guideline states the principle of inclusion in a forthright manner and develops the rationale
for it. Since the guideline lacks the legal force of a regulation or statute, however, it is
comparatively weak. In addition, its reasoning is undermined by its own wording which
suggests a lack of willingness to enforce the guideline, since it is designed to “encourage” and
“promote” inclusion. The Minister of Health may reject an application to market a drug on the
basis that it fails to meet the requirements of the Food and Drug Regulations or that the
application does not contain sufficient information for the Minister to assess the safety of the
drug or of the clinical trial.28 This provision applies to those drugs not yet licensed for marketing
and to those approved drugs being assessed for new uses, formulations and combinations. Since
the inclusion guideline lacks the status of a regulation, it cannot be used directly to reject an
application for failure to meet a regulation. Even though it is arguable that a lack of
representation and analysis could provide the basis for Ministerial rejection on the basis of
inadequacy of the information to assess the safety and efficacy of the drug or the clinical trial,
only regulatory status for the inclusion principle would provide a clear and unequivocal basis for
such a rejection.
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Reviewers of the safety and efficacy of new drug submissions must follow a standard operating
procedure, which normally requires gender-based analysis as an evaluation method in a number
of instances.29 Applying the inclusion guidelines at this stage, reviewers consider how the
clinical trial population represents the population to whom the drug will be marketed. Where a
drug is to be used by women it would be strongly recommended that it be tested on women. A
drug tested only on men, for example, might only be allowed to be marketed to men.30 Gender
might also be considered for safety reasons if a drug is under consideration for a new indication
or if a drug under a notice of compliance with conditions is to go through post-market testing.
The procedure provides at paragraph 4, however, that “[d]eviations from this procedure may be
acceptable, provided the deviations and their justification are documented in the assessment
report.” Further, the instructions are said to be “a guide for reviewers, but the inclusion or
exclusion of information under a section is left to the scientific judgement and discretion of the
reviewer.”31 Timing such review during the safety and efficacy evaluation heightens its potential
to enforce gender inclusion policy. Under the current legislation, the government has most
power to effect changes during the approval process. The Minister is authorized under the
Regulations to withhold approval for failure to meet standards but once the drug has been
approved for marketing, the Food and Drugs Act provides scant authority to require changes. As
Health Canada observes in its 2006 document, Blueprint for Renewal, “[i]ts [the Food and Drugs
Act’s] authorities for compliance and enforcement, based on criminal law, are outdated and
resource intensive, which limits the range of actions that can be taken, including appropriate
sanctions and incentives.”32 Also, no systematic review mechanism to review the inclusion
guideline had been put into place, in spite of the promise in the Women’s Health Strategy of
Health Canada to monitor the inclusion policy for clinical trials.33 The government itself has not
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reviewed the success or failure of its own policies on inclusion providing us little reason to be
optimistic about their implementation.34

The International Conference on Harmonisation [ICH] has brought together six parties (the
governments and pharmaceutical organizations from Japan, the European Union, and the United
States) and three observers (Canada, the World Health Organization, and the European Free
Trade Association), with a view to harmonizing drug approval processes among countries that
choose to incorporate ICH practices into their governing legislation. As Health Canada states on
its website, Canada has adopted and integrated the good clinical practice principles from the ICH
Good Clinical Practice [ICH-GCP] guidelines into its 2001 regulations, though they do not have
the force of law.35 Relying on the ICH-GCP guideline is problematic to some extent because of
the absence of a national regulatory scheme to fill in gaps and the absence of a process to ensure
respect for the guideline.36 The 2001 Canadian regulations contain no explicit reference to
gender equity. The regulatory impact statement analysis lists ICH guidelines that were to be
adopted in Canada.37 These include Guideline E8 (General Consideration of Clinical Trials)
stating the principle that the study population should represent the target population, as in the
Canadian inclusion guideline - and requiring pharmacokinetic information for women in Phase I
along with certain dose-response information to support drug registration. Further, guidelines E3
and M4E require sex-based identification of the patient population, analysis and critical
assessment of the data by sex.38 The impact of these policies is softened, however, by opting out
statements such as “if the size of the study permits”.39 As another example, the E6 (R1) Good
Clinical Practice guideline currently states at 7.3.6, a provision relating to effects in humans,
that, “[a] summary of information on the pharmacokinetics of the investigational product(s)
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should be presented, including the following, if available…[p]opulation subgroups (e.g. gender,
age…).” Once again, the impact of this recommendation is limited by the words “should be
presented” and “if available”.

In March 2007, the Bureau of Women’s Health and Gender Analysis and the Policy
Coordination Division of Health Canada convened a day long conference entitled “Context
Matters: A Health Canada Symposium on Gender, Diversity and Clinical Trials”. The meeting
brought together officials from both the Health Policy and Health Products and Food branches of
Health Canada as well as a number of speakers to consider issues of equity in clinical trials with
an emphasis on achieving greater diversity on the basis of gender, ethnicity (including aboriginal
populations) and age (including children and the elderly). The conference organizers used the
day long symposium as an opportunity to educate Health Canada officials about the importance
of ensuring that gender and diversity considerations are included in the ongoing legislative,
regulatory and policy review. Numerous questions on gender and health were addressed. One
speaker, Yvonne Lefebrve, after reviewing the history of the representation of women in clinical
trials, concluded by suggesting that the outstanding issues are: monitoring and evaluating the
appropriate representation of women in clinical trials and determining whether there is
compliance with current standards/regulations; the sex-based disaggregation of data; the need for
policies regarding equity and conducting international clinical trials; the inclusion of pregnant
women and the representation of diverse groups of women.

Tri-Council Policy Statement, Ethical Conduct for Research Involving Humans
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The TCPS was adopted following extensive negotiations among the three federally funded
granting councils, in order to create a common standard for funded research, regardless of
discipline. The composition of REBs and their mandate to review and approve biomedical
research involving humans and to conduct periodic reviews is set out in the Food and Drug
Regulations.40 The structure and mandate of REBs are also specified in the TCPS, though in
somewhat different terms. Clinical trials must be approved by REBs as part of the Food and
Drugs Act drug approval process.41 Although the Therapeutic Products Directorate has indicated
that all clinical trials are to adhere to the TCPS, a question may be raised about whether this is
enforceable.42 As Mark Hadskis has commented, “[d]etermining when a particular activity is
captured by the TCPS is not always a straightforward matter.”43 The TCPS applies to any
research, defined as systematic inquiry to prove facts, principles or generalizable knowledge that
is directly or indirectly funded by the granting councils. Also, following the requirements of the
TCPS may be a term of private agreements among institutions or be a requirement of regulatory
bodies. Peer-reviewed journals and courts may also promote compliance with the policy
statement.44 The TCPS does not apply in a general manner outside of these contexts.45 The
TCPS is enforced mainly through the denial of funding to proposed research. Rarely, an
institution conducting approved and funded research which turns out to not to conform to TCPS
requirements may be made to return funding.

The TCPS contains one statement dealing primarily with gender equity: that “[w]omen shall not
automatically be excluded from research solely on the basis of sex or reproductive capacity”. 46
In addition, where research is not specific to a group, Article 5.1(a) prohibits researchers from
excluding subjects at the recruitment or research stage based on such attributes as culture, race,
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disability, sex, and so on. These provisions can only be described as weak and ineffectual.47 By
prohibiting only the most egregious exclusions – automatic exclusion solely on sex or
reproductive grounds - they permit even non-arbitrary sex-based exclusion.48 Similarly,
exclusion is permitted when a “valid reason” is offered. The provisions contain no requirement
that samples contain sufficient numbers for sub-sample analysis to be carried out or that such
sub-sample analysis be done. An earlier version of these provisions contained stronger language
which was “gutted” by the councils.49 Françoise Baylis, Jocelyn Downie and Susan Sherwin
have described their reaction to the process: “To our surprise and dismay, the first official draft
Code of Conduct for Research Involving Human Subjects reduced all of the above proposals to a
single prescriptive clause that clearly sought to mask the gendered nature of the problem of
exclusion and underrepresentation….”50

REB review plays a central role in protecting patient safety in the Canadian system. The Law
Commission of Canada’s review of REB governance commented on the excessive and virtually
total reliance on REBs to provide assurance of ethical compliance.51 No formal qualitative
review or accreditation process for REBs exists at this time. Health Canada noted this deficiency
at the time the 2001 Food and Drug Regulations were put into place, and yet justified not placing
more responsibility on REBs than they had already. 52 Currently, the National Council on the
Ethics of Human Research provides organizational oversight and has supported the
implementation of a voluntary accreditation and certification system.53 Trudo Lemmens has
argued in favour of federal oversight of REBs on the ground that REBs have a public mandate to
protect research subjects and the public.54 The variations in the legal force of the multiple laws,
international documents, and guidelines, along with the differences in law applying within
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provincial and territorial jurisdictions, add to the complexity of the task of evaluating proposed
research. The increasing number of multi-site clinical trials and the specialized nature of
research create other demands on local REBs. Kathleen Cranley Glass has described the
structure in these terms: “[t]he current system of research governance is fragmented and
decentralized, without a consistent, accountable, and transparent system of ethics review. We
have yet to establish a comprehensive, uniform set of standards or structure for review that
would apply to all research involving humans. There are no viable systems of education,
accreditation, or monitoring.”55

One significant drawback of the REB system in Canada is the lack of monitoring of clinical trials
and research.56 Although monitoring clinical trials is part of the REB mandate,57 many
institutions provide insufficient support to carry out oversight after the protocol has been
approved. 58 The Therapeutic Products Directorate’s 2002 Inspection Strategy for Clinical Trials
estimated that the Therapeutic Products Directorate would inspect only two per cent of clinical
trials involving human subjects,59 a rate described as the international norm.60

Drug safety
The problems in the area of REB review are compounded by the known deficiencies in the
system of drug approval and oversight. Health Canada has reviewed the drug approval process
and incorporated many of its findings into two documents, Blueprint for Renewal [Blueprint]61
and the revised version following consultation, Blueprint for Renewal II [Blueprint II].62 Most
recently, the Minister of Health has introduced a Bill that, if passed into law, will notably change
Canada’s drug approval process. 63
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A brief consideration of issues facing the drug approval and oversight system in the United
States is helpful. In 2006, the United States Government Accountability Office [GAO], the
investigative arm of Congress, identified serious problems in the FDA’s oversight of safety once
the product reaches the market.64 The 2006 GAO Report considers oversight to have been
compromised by lack of tracking of information about safety issues, lack of criteria to tell both
when safety decisions should be taken and what decisions to take, weak data, and poor decisionmaking processes. In other words, the most powerful drug regulation agency in the world does
not know when or how to make decisions about the safety of drugs. Furthermore, the GAO
report notes that the FDA lacks legal authority in most instances to order a company to carry out
further tests of safety once its product is on the market.

The Institute of Medicine [IOM] released its much-anticipated report on drug safety soon after,
in September 2006.65 This report identifies significant impairments in the drug safety system
resulting from severe funding constraints which weakened scientific analysis of drug safety, a
less than optimal organization culture, and inadequate regulatory authority, most notably with
respect to enforcement. The IOM report includes a lengthy list of recommendations directed to a
fundamental restructuring of the drug approval process. Among the proposals that would have a
significant impact if adopted in Canada are: the limited licensing of new drugs, similar to the
progressive licensing framework supported in Blueprint and Blueprint II; labelling requirements
to warn consumers that the product is a new drug; an advertising ban for new drugs; mandatory
registration of clinical trial results to improve access to drug safety information; and the authority
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to withdraw the product from the market, impose fines and issue injunctions for failure to meet
obligations to carry out safety studies.

While we need to exercise caution in generalizing about drug approval systems, it is clear that
any drug safety system that is broken in such fundamental ways lacks the ability to effectively
promote public safety and health. The deficiencies in drug safety inevitably have an impact on
the ways data on women’s health are gathered, assessed and used. Reforms directed to inclusion
and gender equity will be effective only with a broad overhaul of the drug safety system. In
Canada, the weak “guarantees” of a guideline and a virtually useless research standard are
unlikely to have much impact in a system suffering from its own identified weaknesses.

Canada’s recently introduced Bill to amend the Food and Drugs Act, if enacted, will constitute a
significant restructuring of the drug approval process. The Bill addresses many of the concerns
noted in Blueprint and Blueprint II by developing a progressive licensing framework for drug
approval, setting a new standard for risk assessment, and providing means to secure more
information about product risks. Under the new framework, the Minister is given the power to
grant market approval with conditions, to amend those conditions following notice and a hearing,
to suspend or revoke a clinical trial authorization in particular circumstances, and to grant
licenses for limited uses of drugs. The new standard to be met for drug approval is Ministerial
satisfaction that the benefits provided by the drug outweigh the risks. If adopted, the risk-benefit
standard will mark a change from a more precautionary principle that requires standards to be
met after technical review. The Bill significantly expands the Minister’s power over regulation
and reporting in the post-market period. The Minister will have the power to compel the holder
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of a market authorization or establishment licence to compile information, conduct tests or
studies or monitor experience to obtain additional information relating to the product’s effects on
health or safety or to report this information to the Minister. As well, subject to the Regulations,
the Minister may compel production of information under their control that is considered
necessary to administer the Bill. Significantly, the Bill enables the Minister to require any
labelling necessary to prevent injury to health, a reassessment of a therapeutic product within a
set time, and public disclosure of information about risks and benefits.

Bill C-51 does not directly take up issues of gender equity or sub-population testing, although
those issues may be addressed in the regulations and through the related initiatives being taken
by the government. Blueprint highlights the need to emphasize specific populations in research
and policy, noting possible differences in drug responses to drugs and the need to address
specific needs, 66 Even so, the Bill has implications for achieving gender equity in clinical trials
and drug safety more generally. For one thing, though progressive licensing can be used to
ensure drug safety, it can also be used to approve drugs for marketing more quickly. This latter
possibility may create tension with the goal of promoting safety. Blueprint II indicated that the
government would consider early access mechanisms in its progressive licensing framework to
address the particular therapeutic or health needs of specific populations.67 Earlier availability
can mean that a drug is available earlier to a broader and more representative population than
would have been possible at that stage under the current system, but without necessarily having
completed clinical trials on the full range of populations who will use it. Only if post-market
testing is actually achieved will this change be successful for the entire population who will be
exposed to the drug. With respect to risk management, Women and Health Protection, in their

16

comment on Blueprint, state that an emphasis on “managing risk” would replace the
precautionary principle of health protection. 68 While under the new Bill it is the applicant that
must establish that this risk-benefit standard is met, the terms will be subject to wide
interpretation. Therefore, without some guidance, Ministerial decision-making on this issue
raises the possibility of the politicization of the drug approval process. Because the drug
regulation system operates within government rather than through an arm’s length agency, the
prospect of politicization is real. Finally, with respect to access to therapeutic information or
disclosure, the language of the Bill is permissive, stating that the Minister “may” disclose to the
public information about the risks or benefits associated with a therapeutic product. These
shortcomings may serve to exacerbate whatever inequalities women experience in the clinical
trial/drug safety context.

In contrast to the above concerns, increased oversight in the post-market period greatly favours
drug safety and efficacy for the broader range of groups that will use the drugs once marketing
commences. Significant improvements in the availability and accessibility of information may
be achieved through the new powers to be attributed to the Minister. Specifically, the Minister
will be able to acquire information through the creation of a publicly accessible register of
information, through the potential revealing of confidential business information in certain
circumstances, and through mandatory reporting of adverse drug reactions [ADRs] by prescribed
institutions. The promotional aspects of information distribution are addressed in several
changes addressing criteria for fraud or deception and in a change prohibiting advertisement
unless authorized by the regulations, although the Bill does not address directly the issue of
direct-to-consumer advertising. Strengthened powers of administration and enforcement,

17

expanded powers for inspectors, enhanced remedies for offences, including injunctions, more
realistic fines and imprisonment, application of offences to directors and other persons who are
parties within corporations, and the requirement that sentencing take into account the harm or
risk and vulnerability of consumers are all likely to enhance health information and safety. The
impact of the legislation will depend though on the regulations and on the will of the Minister.

Common law
While we are unable to explore this issue in detail, it is worth raising the question of whether a
tort lawsuit could be successful based on failure to test drugs on women.69 It can be argued that
an action targeting testing inadequacies would provide an important impetus to manufacturers to
include women in their studies, countering the fears of litigation that led drug manufacturers to
exclude women. Litigation on this basis might help persuade the industry that it is in their
interest to include representative samples and to analyze these data. At the same time, one must
ask whether testing drugs on women could itself lead to legal liability. Ellen Wright Clayton has
suggested not, writing, “the risk of incurring liability during the early stages of drug investigation
is actually quite small whereas the potential for substantial liability is much greater once a
fetotoxic drug enters widespread use.”70

Summary
An overview of Canada’s position on gender inclusion in clinical trials reveals numerous
achievements, yet also shortcomings which leave ample room for further development.
Women’s activism and international developments in the United Nations and the United States
have caused the Canadian government to address the issue of how to include women in clinical
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trials so as to come closer to achieving gender equity in health. The government and affiliated
groups have produced policy documents and guidelines. Though perhaps commendable, these
guidelines lack the force of law and do not even attempt to require conduct or check to see
whether goals have been met. These limitations are exacerbated by the drug safety and research
ethics board context within which the guidelines operate. The proposed amendments to the
federal food and drug legislation holds out the promise of increased amounts of health
information and greater control by government over the process; however, it is too soon to say
whether the move to progressive licensing and a risk-benefit standard will enhance or diminish
gender equity. The mechanisms chosen to achieve gender equity remain outside the legislative
framework. Finally, while the threat of tort litigation might induce drug developers to increase
testing of their products on women, this potential cause of action remains untested. The next
section of this paper looks more closely at the role of the pharmaceutical industry in gender
equity in health.

III

The role of the pharmaceutical industry in gender equity in health

One aspect of gender equity in health is the creation of health information that can serve to
improve women’s health. For this reason, the way information is constructed and transmitted
needs to be assessed. Information collected about women’s reactions to drugs is gathered and
filtered through the pharmaceutical company’s promotional lens. The drug industry creates
knowledge about their products in a literal and scientific sense through the process of drug
research, through the presentation of results to the regulator, through publication of research
results in journals, and through promotional activities.71 We have become acutely aware of the
dramatic breakdown in the transmission of reliable information through these channels. For
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example, the cox-2 inhibitor Vioxx was portrayed as a safe and effective means of controlling
pain for arthritis patients and its risks were obscured, as was demonstrated in the Report prepared
by Representative Henry Waxman for the U.S. House Committee on Government Reform, which
provided a rare glimpse of the activities of drug sales representatives (detailers) in their
interactions with doctors.72 Similarly, the antidepressant paroxetine, known as Paxil in North
America and Seroxat in Great Britain, was being used extensively among adolescents until the
BBC program Panorama aired the first in its series of post-market reports on the drug which
stimulated an outpouring of evidence of the significant risk of suicide and suicidal ideation.73

Sources that appear to be neutral and unbiased, such as government advisory panels and peerreviewed journals, have had underlying conflicts of interest unmasked.74 As John Abramson
notes in Overdosed America, drug companies may withdraw advertisements from a journal if
their needs are unmet, while,“[t]he journals benefit from the publicity gained from publishing
large drug company-sponsored studies. This increases the value of their advertising and enables
them to sell back to the drug companies reprints of articles, which the drug companies then
distribute as marketing tools to doctors.”75 Corruption of the information-distribution process
has occurred through ghost-writing of articles by industry, industry-funded patient advocacy
groups, sponsored conferences and selective publication of results.76 As the integrity of the
process is jeopardized and health information is skewed, the accuracy of the information
applying to women comes into question and women’s health is affected.

Promotion by the pharmaceutical industry creates diseases that can be cured by pills – “selling
sickness” or “disease-mongering”, in other words.77 Pharmaceutical products create the image of
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an answer to a “disease” that is aptly described as industry-created, examples being social
anxiety disorder or baldness. The dual myths of the need for intervention and of the need for a
particular drug’s intervention are created through these images.78 Intervention through dealing
with underlying problems linked to the social determinants of health has no appeal to the drug
industry. Poverty, chronic joblessness, social environments, gender and culture, and a range of
other social determinants influence health and access to the health system. Buying into the
pharmaceutical model – interventionist, individualistic, technological – leads individuals and
governments away from the collective, community-focused and preventive public health
solutions. The social determinants of health approach is linked to gender-based analysis, which
helps us to understand how the experiences of women and men are different and similar and how
health status, health needs and health care utilization differ.79 Pharmaceutical intervention
ignores these links.

These flaws in the construction and transmission of health information have an impact on gender
equity. Distortions in data diminish the impact of gender inclusion policies. Gender
representation in research is essential to creating knowledge about the impact of drugs on the
experiences of women and men. Unless the research is done, and the results accurately
conveyed to all who need them, the impact on women’s health will likely be unjust.

ADR data need be comprehensively examined to determine whether and how gender is a
factor. Women have been found to experience more ADRs than men. This result is
sometimes attributed to women’s greater exposure to health professionals and higher level
of drug-taking. Bates and Leape have reported on studies that indicate that women have a
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rate of ADRs 50% higher than men and consider whether these rates may be affected not
only by the greater frequency of medical attention and drugs but also by the periods of
women’s lives when pharmacokinetics are affected: menarche, pregnancy and delivery,
lactation, and menopause. 80 Could it also result from lack of knowledge about the impact
of drugs on women, or on particular groups of women? Beard and Lee81 have noted that,
“[i]n general, women appear to be at greater risk of ADRs than men. Female patients
appear to have a 1.5-1.7-fold greater risk of developing an ADR.82 The reasons for this are
not entirely clear, but include gender-related differences in pharmacokinetic,
immunological and hormonal factors, as well as differences in the pattern of medicine use.”
Elderly women, who make up the majority of elderly people, take multiple prescriptions
whose interaction effects remain largely unstudied. Boxer and Shore have described the
impact in these terms: “[a]dverse drug reactions occur about twice as often in older than
younger patients…Risk of an adverse drug reaction increases with greater severity of
illness, multiple comorbidities, smaller body size, changes in hepatic and renal metabolism
and excretion, and prior drug reactions.” 83 Studies demonstrate the lack of inclusion and
representation of those who will use drugs, with specific reference to elderly patients. One
study notes, “NSAIDs are commonly used in elderly people because of the high prevalence
of musculoskeletal disorders, especially in women. However, in the major drug trials
evaluating NSAIDs, only 2.1% of patients were 65 years of age or over and less than 0.1%
were over 75. In practice, elderly people are among the largest users of drugs and have the
highest incidence of serious drug-related side effects.”84
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In light of these and similar flaws in gathering health information, we have several
recommendations for change in the pharmaceutical industry and in regulatory oversight. First,
knowledge about drug reactions needs to be collected in a broad and systematic manner. The
Canadian system, like the American, collects drug information through mandatory reporting by
drug companies to government and through voluntary reporting by doctors and hospitals. It is
possible for Canadian consumers to report directly online, but the weight given to self-reporting
is not indicated. When the BBC program Panorama ran the first of its series of programs on the
antidepressant Seroxat, they received 1374 emails, as well as letters and 862 website
communications from viewers who described their own experiences with the drug. An analysis
of these results concluded that the picture created by reading the reports provided more complete
data, including reports of suicides that had not been reported to the British authorities, and
contained the context of the events so that the data could be evaluated and the impact on health
more realistically assessed.85 Another study looks at the printouts of reports from the Yellow
Cards submitted by physicians and other health professionals over 12 years (1990-2002) on
adverse effects of paroxetine. Comparing the professional reports with the reports from patients
in the previous study, the authors observe that patient reports “communicate essential
information which professional reporters can never be expected to provide. In this case, patients
provided reports that were much richer in their descriptions of behavioural phenomena and
feelings than the YC [Yellow Card] reports and often much better at explaining the nature,
significance and consequences of adverse drug effects. Patient reports convert the more
technical terms that professionals use into understanding.”86
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The voluntary reporting system results in significant underreporting of adverse events, at a level
estimated at 10 per cent of what had been experienced and even the study of the mandatory
Yellow Card system found a significant degree of underreporting.87 Patient safety is jeopardized
when early identification of risks is undermined, particularly in the immediate post-market
period when the number of individuals exposed to drugs is significantly increased and the drug is
provided to people on whom the drug was not tested. As women experience more ADRs than
men, this risk falls disproportionately on women. While Canada’s proposed legislative changes
would require ADR reporting by prescribed classes of institutions prescribed by the regulations,
this is only a first step.

Adverse effects data-gathering must become much more efficient, accurate and contextual in
order to protect public health. Health Canada has suggested several approaches to remedy the
current deficiencies, including requiring industry to make a submission prior to approval of their
plans for pharmacovigilance in the post-market period; establishing the authority under the
Regulations to require post-market studies; collaborating to develop head-to-head comparison
studies and large observational studies; addressing under-reporting; developing active
surveillance systems; and increasing government’s capacity to assess safety signals. 88 Another
way to achieve this goal is by paying attention to and recording patient descriptions of adverse
reactions. The deficiencies of the adverse effect reporting system in Canada have been on Health
Canada’s radar for decades and it is time for these useful suggestions to be fully assessed and
implemented.
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Next, reliable sources of information that are fully independent of the industry are needed to
maintain the integrity of the public process and restore confidence in the system. An
independent evaluator of information is also required to inquire into such issues as gender
inclusion and drug advertising. Having industry pay to have clinical trial data evaluated in the
process of drug approval in the United States has led to speedy trials, but these have been linked
to a higher level of drug recalls. Eight out of ten drugs withdrawn by the FDA between 1997 and
2000 – a very high rate of withdrawal in itself – had greater health risks for women.89

Also, doctors and patients need to be made fully aware of the populations on whom the drug has
been tested and the results.90 Access needs to be given to data submitted during the approval
process, and unless it is, doctors and patients will lack information that is vital to decisionmaking.91 To give meaningful access, the government would need to require release of data from
companies concerned about revealing trade secrets, as in the proposed legislation. 92

Finally, a strong need exists to monitor the inclusion of representative populations through an
independent entity. Such an entity should also review drug advertising to prevent the use of
stereotypes and to prevent promotion from undermining disclosure. Advertisements directed to
prescribing professionals need to be subject to enhanced scrutiny on this basis, supported by
regulations. Direct-to-consumer advertising, ostensibly prohibited in Canada, needs to be
prohibited in fact. An independent agency could assist in monitoring the distribution of
broadcast, print and on-line ads. Several authors have suggested that an independent entity of
this sort should review the clinical trials process as a whole.93
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IV. Conclusion
The Canadian government has indicated its strong support for gender equity through its policy
statements, institutional structures and guidelines. At the same time, it has not fully translated
these aspirations into concrete achievements, either by enacting legislation or through
administrative oversight. In considering the ways the pharmaceutical industry presents drug
information and in the over-emphasis on research ethics board review as the mechanism for
monitoring the ethical aspects of drug trials, it is apparent that there is room for improvement in
achieving the aspirations of the inclusion policy. We have pointed to the need for specific
reforms in the areas of drug approval and the creation of knowledge about drugs as a means to
realize these goals. Gender inclusion has significant health rewards for women. Achieving
inclusion requires a commitment to using effective legislative and administrative mechanisms,
including those that will enhance safety and the provision of health information, to achieve the
benefits of the inclusion commitment.
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